Chronic Hand Eczema (CHE): A Narrative Review
Abstract Chronic hand eczema (CHE) is a common and challenging skin condition, characterized by persistent hand dermatitis which lasts over 3 months or recurs at least twice a year. This condition is often multifactorial, involving genetic predispositions, environmental factors and triggers, such as...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-03-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01365-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850154048624263168 |
|---|---|
| author | Gioele Ghezzi Costanza Falcidia Giovanni Paolino Santo R. Mercuri Alessandra Narcisi Antonio Costanzo Mario Valenti |
| author_facet | Gioele Ghezzi Costanza Falcidia Giovanni Paolino Santo R. Mercuri Alessandra Narcisi Antonio Costanzo Mario Valenti |
| author_sort | Gioele Ghezzi |
| collection | DOAJ |
| description | Abstract Chronic hand eczema (CHE) is a common and challenging skin condition, characterized by persistent hand dermatitis which lasts over 3 months or recurs at least twice a year. This condition is often multifactorial, involving genetic predispositions, environmental factors and triggers, such as irritants and allergens. Studies show a higher incidence in women, though prevalence estimates vary across different age groups. The pathogenesis involves complex immune mechanisms, particularly Th1/Th2 cell responses. Clinically, CHE presents in various forms, with symptoms such as redness, scaling and itching that significantly impact patients’ quality of life. Treatment approaches are diverse. While emollients and topical corticosteroids have historically been the mainstay, new systemic therapies like JAK inhibitors and biologics are progressively being used for severe cases. Key molecular targets comprise interleukin (IL)-4 and IL-13, the JAK-STAT pathway, phosphodiesterase 4 (PDE4) and chemoattractant chemokines. Managing CHE effectively remains a challenge because of its chronicity and the variability in individual responses to treatment. However, emerging therapeutic strategies will help clinicians to offer more patient-centred approaches. |
| format | Article |
| id | doaj-art-7123ef0624e541f384b5b564610250c1 |
| institution | OA Journals |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-7123ef0624e541f384b5b564610250c12025-08-20T02:25:34ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-03-0115477179510.1007/s13555-025-01365-7Chronic Hand Eczema (CHE): A Narrative ReviewGioele Ghezzi0Costanza Falcidia1Giovanni Paolino2Santo R. Mercuri3Alessandra Narcisi4Antonio Costanzo5Mario Valenti6Dermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalUnit of Dermatology, IRCCS San Raffaele HospitalUnit of Dermatology, IRCCS San Raffaele HospitalDermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalAbstract Chronic hand eczema (CHE) is a common and challenging skin condition, characterized by persistent hand dermatitis which lasts over 3 months or recurs at least twice a year. This condition is often multifactorial, involving genetic predispositions, environmental factors and triggers, such as irritants and allergens. Studies show a higher incidence in women, though prevalence estimates vary across different age groups. The pathogenesis involves complex immune mechanisms, particularly Th1/Th2 cell responses. Clinically, CHE presents in various forms, with symptoms such as redness, scaling and itching that significantly impact patients’ quality of life. Treatment approaches are diverse. While emollients and topical corticosteroids have historically been the mainstay, new systemic therapies like JAK inhibitors and biologics are progressively being used for severe cases. Key molecular targets comprise interleukin (IL)-4 and IL-13, the JAK-STAT pathway, phosphodiesterase 4 (PDE4) and chemoattractant chemokines. Managing CHE effectively remains a challenge because of its chronicity and the variability in individual responses to treatment. However, emerging therapeutic strategies will help clinicians to offer more patient-centred approaches.https://doi.org/10.1007/s13555-025-01365-7Chronic hand eczemaTherapeuticsAtopic dermatitisHand dermatitis |
| spellingShingle | Gioele Ghezzi Costanza Falcidia Giovanni Paolino Santo R. Mercuri Alessandra Narcisi Antonio Costanzo Mario Valenti Chronic Hand Eczema (CHE): A Narrative Review Dermatology and Therapy Chronic hand eczema Therapeutics Atopic dermatitis Hand dermatitis |
| title | Chronic Hand Eczema (CHE): A Narrative Review |
| title_full | Chronic Hand Eczema (CHE): A Narrative Review |
| title_fullStr | Chronic Hand Eczema (CHE): A Narrative Review |
| title_full_unstemmed | Chronic Hand Eczema (CHE): A Narrative Review |
| title_short | Chronic Hand Eczema (CHE): A Narrative Review |
| title_sort | chronic hand eczema che a narrative review |
| topic | Chronic hand eczema Therapeutics Atopic dermatitis Hand dermatitis |
| url | https://doi.org/10.1007/s13555-025-01365-7 |
| work_keys_str_mv | AT gioeleghezzi chronichandeczemacheanarrativereview AT costanzafalcidia chronichandeczemacheanarrativereview AT giovannipaolino chronichandeczemacheanarrativereview AT santormercuri chronichandeczemacheanarrativereview AT alessandranarcisi chronichandeczemacheanarrativereview AT antoniocostanzo chronichandeczemacheanarrativereview AT mariovalenti chronichandeczemacheanarrativereview |